🇺🇸 FDA
Patent

US 12383631

Immune antigen specific IL-18 immunocytokines and uses thereof

granted A61KA61K47/6813A61K47/6849

Quick answer

US patent 12383631 (Immune antigen specific IL-18 immunocytokines and uses thereof) held by Bright Peak Therapeutics AG expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Bright Peak Therapeutics AG
Grant date
Tue Aug 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K47/6813, A61K47/6849, A61K47/6851, A61K47/6863